Rev. ed of: How to understand acid-base. c1981.

The book is a concise and informative text about acid-base disorders. The book begins with very simple mathematics, chemistry, and physiological concepts and smoothly connects these to various aspects of acid-base disturbances and blood gas disorders through many simple-to-understand case-based examples. It covers various important topics such as respiratory acidosis and alkalosis, metabolic acidosis and alkalosis, mixed disorders, arterial blood gas, etc. All chapters end with a simple take-home summary facilitating better understanding and recall value. This book showcases practical text important at all levels of medical education, right from a basic science student to an attending physician/surgeon. Students, interns, residents, fellows, and attending physicians working in a broad range of clinical settings, particularly anesthesiology, surgery, and critical care can find this book helpful.

This book provides a concise yet comprehensive overview of acid-base disorders. Each chapter reviews an acid-base disorder, covering pathophysiology, evaluation, and management of the disorder. The chapters also include clinical cases and a Q&A section, based on scenarios and questions that clinicians regularly encounter when treating patients with these disorders. The book concludes with two chapters on acid-based disorders in special patient populations, including critically ill patients, pregnant patients, and surgical patients. Written by an expert in the field, Acid-Base Disorders: Clinical Evaluation and Management is a state-of-the-art resource that should assist clinicians and practitioners in managing patients with acid-base disorders.

Featuring the work one of the world's foremost authorities on rubber curing, this uniquely comprehensive resource provides valuable data that will allow researchers and engineers to find solutions to their own curing problems. It delves into a variety of current evaluation practices for unvulcanized and vulcanized rubber and curing methods, i

Prostaglandins, Leukotrienes, and Cancer is a multi-volume series that will focus on an emerging area of cancer research. In 1968, R.H. Williams first reported that elevated prostaglandin levels are present in human medullary car­ cinoma. Since that time, the concept that arachidonic acid metabolites may be in­ volved in cancer has expanded to include every aspect of the disease from cell transformation through metastasis. Prostaglandins and leukotrienes are generic terms used to describe a family of bioactive lipids produced from unsaturated fatty acids (principally from arachidonic acid) via the cyclooxygenase and lipoxygenase pathways, respec­ tively. Cyclooxygenase products consist of diverse products such as prosta­ glandin E, (POE,), prostacyclin (POI2) and thromboxane A2 (TXA2), whereas lipoxygenase products consist of hydroperoxy fatty acids and mono-, di- and tri-hydroxy acids including leukotrienes. The precursor fatty acids for the cyclooxygenase and lip oxygenase pathways are present in cellular phospholipids. This finding established an important control point in their biosynthesis-the release of substrate. This occurs in response to numerous stimuli that act at the cell surface. Dr. Bengt Samuelsson's extensive study of the metabolism of pros­ taglandins indicated that they are rapidly inactivated on a single pass through pulmonary circulation. Thus, they cannot act as circulating hormones and appear to be made on demand in or in the vicinity of target tissues leading to the concept that prostaglandins are local hormones or autocoids.

The American Obesity Association identifies obesity's link to numerous medical conditions, including hypertension, type 2 diabetes, cardiovascular disease, several cancers, and a host of inflammatory disorders. Evidence indicates that inflammation has more than a corollary relation with obesity; that in fact, obesity itself manifests a low-grade, m